Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary efficacy analysis of a randomized phase III trial.

被引：0
|
作者：
Polikoff, J
Mitchell, EP
Badarinath, S
Graham, CD
Jennis, A
Chen, TT
Gustafson, TN
Langer, C
机构：
[1] Kaiser Permanente, San Diego, CA USA
[2] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[3] Florida Oncol Assoc, Jacksonville, FL USA
[4] Charleston Canc Ctr, Charleston, SC USA
[5] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：264S / 264S
页数：1
相关论文
共 50 条
  • [21] Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX
    Lledo, Gerard
    Huguet, Florence
    Chibaudel, Benoist
    Di Fiore, Frederic
    Mineur, Laurent
    Galais, Marie-Pierre
    Artru, Pascal
    Blondin, Valerie
    Dupuis, Olivier
    Abdiche, Menouar Samir
    Jovenin, Nicolas
    Pozet, Astrid
    Bonnetain, Franck
    Attia, Mohamed
    Dahan, Laetitia
    de Gramont, Aimery
    EUROPEAN JOURNAL OF CANCER, 2016, 56 : 115 - 121
  • [22] Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX in RAS wild-type patients with initially unresectable colorectal liver metastases: The TRICE randomized clinical trial
    Li, Y.
    Wang, D.
    Ren, C.
    Li, S-S.
    Fong, W. Pat
    Wu, X.
    Xiao, J.
    Yuan, Y.
    Li, B-K.
    Ding, P-R.
    Wang, Z.
    Wang, F.
    Pan, Z.
    Chen, G.
    Wang, X-Z.
    Wang, L-Y.
    Chen, T.
    Liu, T.
    Yuan, Y.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S413 - S414
  • [23] EPIC:: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
    Sobrero, Alberto F.
    Maurel, Joan
    Fehrenbacher, Louis
    Scheithauer, Werner
    Abubakr, Yousif A.
    Lutz, Manfred P.
    Vega-Villegas, M. Eugenia
    Eng, Cathy
    Steinhauer, Ernst U.
    Prausova, Jana
    Lenz, Heinz-Josef
    Borg, Christophe
    Middleton, Gary
    Kroening, Hendrik
    Luppi, Gabriele
    Kisker, Oliver
    Zubel, Angela
    Langer, Christiane
    Kopit, Justin
    Burris, Howard A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (14) : 2311 - 2319
  • [24] A randomized, open-label phase 11 study evaluating the efficacy and safety of FOLFOX6+Cetuximab versus FOLFIRI plus Cetuximab as first-line therapy in patients with metastatic colorectal cancer
    Ciuleanu, T. E.
    Scheithauer, W.
    Kurteva, G.
    Ocvirk, J.
    Koza, I.
    Papamichael, D.
    Wenczl, M.
    Brodowicz, T.
    Zielinski, C. C.
    Beslija, S.
    EJC SUPPLEMENTS, 2007, 5 (04): : 249 - 249
  • [25] A randomized, open-label cecog phase II study evaluating the efficacy and safety of FOLFOX6+cetuximab and FOLFIRI plus cetuximab as first-line therapy in metastatic colorectal cancer (MCRC)
    Ciuleanu, T.
    Scheithauer, W.
    Kurteva, G.
    Ocvirk, J.
    Koza, I
    Papamichael, D.
    Vrbanec, D.
    Brodowicz, T.
    Beslija, S.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 26 - 26
  • [26] Steroid-free regimen with aprepitant in preventing chemotherapy-induced nausea and vomiting in patients with colorectal cancer receiving FOLFOX chemotherapy: A randomized phase III trial.
    Wang, Wenjing
    Ling, Jiayu
    Cai, Yue
    Zhang, Jianwei
    Hu, Huabin
    Li, Shanshan
    Xiao, Jian
    Deng, Yanhong
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [27] Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer
    Ozaslan, Ersin
    Topaloglu, Ulas Serkan
    Inanc, Mevlude
    Erdem, Umut Gokmen
    Demir, Hacer
    Arpaci, Erkan
    Seker, Mehmet Metin
    Karaaga, Mustafa
    Kiziltepe, Melih
    Eker, Baki
    Ozkan, Metin
    JOURNAL OF BUON, 2017, 22 (04): : 863 - 868
  • [28] The efficacy and safety of anlotinib in refractory colorectal cancer: A double-blinded, placebo controlled, randomized phase III ALTER0703 trial.
    Chi, Yihebali
    Shu Yongqian
    Ba Yi
    Bai Yuxian
    Qin Baoli
    Wang Xiuwen
    Xiong Jianping
    Xu Nong
    Zhang Helong
    Xu Jianming
    Cheng Ying
    Feng Jifeng
    Hu Chunhong
    Chen Yigui
    Chen Zhendong
    Wang Jufeng
    Dang Chenxue
    Cai Jianqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [29] FOLFOX-6 PLUS IMATINIB, BEVACIZUMAB AND CETUXIMAB IN ADVANCED UNTREATED COLORECTAL CANCER
    Andretta, V
    Bennicelli, E.
    Pessino, A.
    Caprioni, F.
    Decian, F.
    Di Benedetto, M.
    Sobrero, A.
    ANNALS OF ONCOLOGY, 2009, 20 : 113 - 113
  • [30] Who should be considered for FOLFOX adjuvant chemotherapy? An analysis of Dukes B colorectal cancer in a Royal Marsden Hospital randomized trial.
    Chua, YJ
    Norman, AR
    Wotherspoon, A
    Cunningham, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 260S - 260S
12345